332 related articles for article (PubMed ID: 15015604)
21. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
22. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
[TBL] [Abstract][Full Text] [Related]
23. Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients.
Paradiso A; Tommasi S; Barletta A; Leone B; Lacava J; Vellejo C; Labriola A; Marzullo F; Altieri R; Schittulli F; De Lena M
Anticancer Res; 1999; 19(5C):4523-8. PubMed ID: 10650804
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
25. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.
Buffa FM; Bentzen SM; Daley FM; Dische S; Saunders MI; Richman PI; Wilson GD
Clin Cancer Res; 2004 Jun; 10(11):3745-54. PubMed ID: 15173081
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
Seitz G; Bonin M; Fuchs J; Poths S; Ruck P; Warmann SW; Armeanu-Ebinger S
Int J Oncol; 2010 Feb; 36(2):491-500. PubMed ID: 20043085
[TBL] [Abstract][Full Text] [Related]
27. [Protein expression of p53, bcl-2, and bax in adenoid cystic carcinoma of lacrimal gland].
You JQ; Wang P
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1978-82. PubMed ID: 19062739
[TBL] [Abstract][Full Text] [Related]
28. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors?
Zafirellis K; Karameris A; Milingos N; Androulakis G
Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of Deoxyribonucleic acid (DNA) image analysis cytometry and immunohistochemical expression of Ki67 in surgically resected non-small cell lung cancers.
Maounis NF; Chorti M; Apostolakis E; Ellina E; Blana A; Aggelidou M; Dritsas I; Markidou S
Cancer Detect Prev; 2006; 30(6):507-14. PubMed ID: 17113721
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
31. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry.
Wachtel M; Runge T; Leuschner I; Stegmaier S; Koscielniak E; Treuner J; Odermatt B; Behnke S; Niggli FK; Schäfer BW
J Clin Oncol; 2006 Feb; 24(5):816-22. PubMed ID: 16391296
[TBL] [Abstract][Full Text] [Related]
32. Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck.
Staibano S; Lo Muzio L; Pannone G; Scalvenzi M; Salvatore G; Errico ME; Fanali S; De Rosa G; Piattelli A
Anticancer Res; 2001; 21(6A):3757-64. PubMed ID: 11911244
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
35. [Fragile histidine triad expression in rhabdomyosarcoma].
Wang SL; Yang GH; Bu H; Guo LX; Zhou Q; Zhang HY; Ye L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar; 35(2):176-8. PubMed ID: 15071908
[TBL] [Abstract][Full Text] [Related]
36. Epithelial cell turnover, p53 and bcl-2 protein expression during oncogenesis of early and advanced gastric cancer in a Western population.
Triantafyllou K; Kitsanta P; Karamanolis DG; Kittas C; Ladas SD
Dig Liver Dis; 2008 Jan; 40(1):39-45. PubMed ID: 18063429
[TBL] [Abstract][Full Text] [Related]
37. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53.
Meara RS; Cangiarella J; Simsir A; Horton D; Eltoum I; Chhieng DC
Cytopathology; 2007 Oct; 18(5):283-9. PubMed ID: 17883690
[TBL] [Abstract][Full Text] [Related]
38. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
39. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry.
Porichi O; Nikolaidou ME; Apostolaki A; Tserkezoglou A; Arnogiannaki N; Kassanos D; Margaritis L; Panotopoulou E
Anticancer Res; 2009 Oct; 29(10):3977-82. PubMed ID: 19846939
[TBL] [Abstract][Full Text] [Related]
40. Bio-pathological factors of prognostic value in colorectal adenocarcinomas.
Mottolese M; Buglioli S; Piperno G; Sperduti I; Giannarelli D; D'Angelo C; Cosimelli M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):163-6. PubMed ID: 16767924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
